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Venezuelan equine encephalitis virus (VEE) is an important equine and human pathogen of the Americas.
In the adult mouse model, cDNA-derived, virulent V3000 inoculated subcutaneously (s.c.) causes high-titer
peripheral replication followed by neuroinvasion and lethal encephalitis. A single change (G to A) at nucleotide
3 (nt 3) of the 5* untranslated region (UTR) of the V3000 genome resulted in a virus (V3043) that was avirulent
in mice. The mechanism of attenuation by the V3043 mutation was studied in vivo and in vitro. Kinetic studies
of virus spread in adult mice following s.c. inoculation showed that V3043 replication was reduced in peripheral
organs compared to that of V3000, titers in serum also were lower, and V3043 was cleared more rapidly from
the periphery than V3000. Because clearance of V3043 from serum began 1 to 2 days prior to clearance of
V3000, we examined the involvement of alpha/beta interferon (IFN-a/b) activity in VEE pathogenesis. In
IFN-a/bR2/2 mice, the course of the wild-type disease was extremely rapid, with all animals dying within 48 h
(average survival time of 30 h compared to 7.7 days in the wild-type mice). The mutant V3043 was as virulent
as the wild type (100% mortality, average survival time of 30 h). Virus titers in serum, peripheral organs, and
the brain were similar in V3000- and V3043-infected IFN-a/bR2/2 mice at all time points up until the death
of the animals. Consistent with the in vivo data, the mutant virus exhibited reduced growth in vitro in several
cell types except in cells that lacked a functional IFN-a/b pathway. In cells derived from IFN-a/bR2/2 mice,
the mutant virus showed no growth disadvantage compared to the wild-type virus, suggesting that IFN-a/b
plays a major role in the attenuation of V3043 compared to V3000. There were no differences in the induction
of IFN-a/b between V3000 and V3043, but the mutant virus was more sensitive than V3000 to the antiviral
actions of IFN-a/b in two separate in vitro assays, suggesting that the increased sensitivity to IFN-a/b plays
a major role in the in vivo attenuation of V3043.
Venezuelan equine encephalitis virus (VEE) is a member of
the Alphavirus genus in the Togaviridae family. The genome of
this enveloped virus is a single-stranded, messenger-sense
RNA molecule of approximately 11.5 kb (24), capped at the 59
end and polyadenylated at the 39 end. The genomic RNA
encodes four nonstructural proteins (nsP1 through -4) and
three structural proteins (capsid and two envelope glycopro-
teins, E1 and E2). The 59 untranslated region (UTR) in VEE
is 45 nucleotides (nt) long, and although its sequence is not
conserved among alphaviruses, the sequence predicts a stem-
loop structure that is conserved across the Alphavirus genus
(55). It has been proposed that the complementary sequence at
the 39 end of the minus strand also folds into a conserved
secondary structure that may play a role as a promoter for the
initiation of genome RNA synthesis from the minus-strand
template (10, 38, 55). The nonstructural proteins are translated
directly from the genomic RNA as a polyprotein that is cleaved
by a viral protease to produce the enzyme complex necessary
for RNA replication. Thus, the 59 UTR is likely involved both
in translation of genomic mRNA and in initiation of plus-
strand RNA synthesis through interactions with host and/or
viral proteins. The structural proteins are expressed from an
abundant 26S subgenomic mRNA as a polyprotein. The pre-
cursor is cleaved into the capsid protein that assembles to form
the T54 nucleocapsid, as well as into two transmembrane
glycoproteins, E1 and E2, that are arranged within the viral
envelope in a T54 icosahedral lattice (39, 50).
VEE is an arthropod-borne virus that has been associated
with periodic epidemics and equine epizootics in the Western
Hemisphere since the 1920s. These epidemics are associated
with high mortality (19 to 83%) and severe morbidity in
equines and with up to tens of thousands of human cases, with
a case mortality rate of around 1% (21, 46, 61). Recent studies
indicate that epizootic viruses can evolve from enzootic
equine-avirulent strains that circulate continuously among wild
rodents and Culex melanoconio mosquitoes in lowland tropical
forests (43, 60). The mechanism of emergence and the molec-
ular determinants of natural equine virulence have been ex-
amined recently but are not well understood (34, 42).
Experimental infection of the adult mouse with VEE closely
parallels the biphasic disease seen in horses (12). In the mouse,
subcutaneous (s.c.) inoculation with VEE is followed by initial
viral replication in the draining lymph nodes (DLN), viral
spread to all of the major lymphoid organs, and a significant
viremia. This peripheral infection is cleared by 3 to 4 days
postinfection (p.i.). In the second phase, VEE invades the
central nervous system first through the olfactory and trigem-
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inal nerves, replicating predominantly in neurons and causing
lethal encephalitis (6, 13).
Molecular determinants of VEE virulence in the mouse
model have been studied using cDNA clones of wild-type vir-
ulent VEE and tissue culture-adapted, attenuated strains, in-
cluding the investigational live-attenuated vaccine strain TC-83
(2, 9, 13, 23, 40, 51). TC-83 was derived by serial passage of the
virulent epizootic VEE Trinidad donkey strain (VEE-TRD) in
guinea pig heart cells (3). Comparison of the nucleotide se-
quences of TRD and TC-83 revealed 12 nucleotide changes.
Mouse virulence studies of chimeric TRD–TC-83 viruses sug-
gested that two changes were associated with the attenuated
phenotype, a G-to-A substitution at nt 3 in the 59 UTR and an
E2-120 Thr-to-Arg mutation (23). It was suggested that the 59
UTR and the E2-120 mutations represent two independent
loci that act synergistically in the attenuation of TC-83. The
contributions of several individual mutations in E1 and E2
glycoproteins to VEE virulence in mice have been well char-
acterized (4, 9, 13). However, the role of the 59 UTR in the
attenuation of VEE has not been addressed separately.
The involvement of alpha/beta interferon (IFN-a/b) in the
virulence of VEE for hamsters and mice was first proposed
more than 25 years ago, when pairs of virulent and benign
isolates were compared with respect to their sensitivity to IFN-
a/b in cultures of hamster cells or in vivo in hamsters (20, 22).
These early studies showed a correlation between virulence
and relative resistance to IFN-a/b. More recently, the IFN-a/b
sensitivity of TC-83 and 24 enzootic and epizootic isolates of
VEE were compared in a tissue culture cytopathic effect (CPE)
reduction assay (54). The IFN-a/b resistance or sensitivity phe-
notype correlated with the epizootic or enzootic potential,
respectively, supporting the idea that one of the adaptations
leading to the emergence of epizootic strains is the evolution of
resistance to IFN-a/b (54). The IFN-a/b sensitivity or resis-
tance phenotype of chimeric viruses containing the 59 UTR
and nonstructural genes from either enzootic (sensitive) or
epizootic (resistant) strains of VEE seems to segregate with
the 59 UTR and nonstructural genes of the parental strain,
even though it does not segregate with genes conferring guinea
pig virulence (42).
Viral double-stranded RNA (dsRNA) replication interme-
diates are major inducers of the IFN-a and IFN-b genes and
cofactors in the activation of IFN-induced antiviral enzymes
(49, 56, 62). Since cis-acting sequences involved in the regula-
tion of alphavirus RNA replication are in the 59 UTR (55), it
is possible that virulence determinants in the 59 UTR of the
VEE genome might act through either a direct effect on viral
replication and yield and/or an indirect effect on early host
responses, such as IFN-a/b.
Noncoding regions of many viral genomes carry virulence
determinants, including picornaviruses, influenza virus, retro-
viruses, and other alphaviruses (1, 10, 36, 41, 44). For the
prototype alphavirus, Sindbis virus, 59 UTR mutants typically
show defects in RNA accumulation and altered growth rates in
cell culture (37). A single nucleotide change in the 59 UTR of
Sindbis virus confers neurovirulence in rats (26). However, the
pathogenic mechanism at the molecular level has not been
elucidated for these alphavirus noncoding viral determinants.
In this study, the mutation in the 59 UTR of the TC-83
genome was evaluated as to its effect on mouse virulence. A
single change (G to A) in nt 3 of the 59 UTR of the virulent
V3000 genome resulted in a virus, V3043, that was avirulent in
mice and had reduced growth in cell culture. In delineating the
mechanism of attenuation in vivo and in vitro, two possibilities
were considered: an intrinsic defect in viral replication and an
altered interaction with the innate immune response. Full-
length cDNA clones of the virulent parent (V3000) and single-
site mutant (V3043) genomes were used as genetically stable
sources of homogeneous virus for infections of mice with a
targeted disruption of the IFN-a/b receptor gene and infec-
tions of cells derived from these mice (35). In the absence of a
functional IFN-a/b pathway, V3043 replicated like V3000 in
vivo and in vitro. Our results demonstrated that IFN-a/b plays
a major role in the pathogenesis of V3000 and in the attenu-
ated phenotype of the 59 UTR mutant V3043. One mechanism
is an increased sensitivity of V3043 to the antiviral actions of
IFN-a/b.
MATERIALS AND METHODS
Viruses. The construction of the full-length cDNA clone pV3000, derived from
the natural VEE isolate, TRD, has been described previously (9). Nucleotide 3
of the 59 UTR was changed from G to A by site-directed mutagenesis. The
500-bp XbaI-RsrII fragment of pV3000 was replaced with the mutant fragment to
produce pV3043, and the sequence of the replaced fragment was confirmed. To
produce virus stocks, pV3000 and pV3043 were transcribed in vitro and the
infectious RNA was electroporated into baby hamster kidney cells (BHK-21;
ATCC CCL-10) as described previously (8). Virus particles were harvested from
the supernatant at 24 h p.i. (hpi) when significant CPE was produced and were
clarified by centrifugation (10,000 3 g, 30 min, 4°C) and stored as single-use
aliquots at 270°C. Virus titers were determined by a standard plaque assay on
BHK-21 cells. For some experiments, virus stocks were concentrated by pelleting
the clarified virus preparations through 20% (wt/vol) sucrose in low-endotoxin
phosphate-buffered saline (PBS) at 71,934 3 g for 5 h at 4°C.
VEE replicon particles (VRP) expressing green fluorescent protein (GFP)
were packaged using a split helper system as described previously (45). The
wild-type replicon plasmid pV5005 contained the gene for GFP mutant 2 (7)
directly downstream of the 26S promoter, in place of the VEE structural protein
genes (31). A mutant replicon genome containing the nt 3 G-to-A (nt3A) mu-
tation, pV5505, was constructed by substituting the 546-bp XbaI-RsrII fragment
from V3043 for the equivalent fragment in the pV5005 plasmid and confirmed by
sequencing. Wild-type and mutant VRP were produced by coelectroporation
into BHK-21 cells of RNA transcripts from pV5005 or pV5505, respectively, with
two VEE helper transcripts expressing either the capsid or glycoprotein genes, as
described previously (31). The capsid and glycoprotein helpers were of wild-type
origin (V3000); therefore, wild-type and nt3A mutant VRP were denoted V5005-
3000 and V5505-3000, respectively. Due to the lack of structural protein genes,
infectious VRP undergo only one round of infection. The titers of VRP stocks
were determined by the infection of BHK-21 cells with serial dilutions followed
by counting the number of GFP-expressing BHK-21 cells by using a fluorescent
microscope (Nikon) with a fluorescein isothiocyanate filter set. Titers were ex-
pressed as infectious units (IU) per milliliter.
Mouse studies. Specific-pathogen-free female CD-1 mice were obtained from
Charles River Breeding laboratories (Raleigh, N.C.). Breeding pairs of IFN-a/
bR1/1 129Sv/Ev and IFN-a/bR2/2 mice were kindly provided by Herbert Virgin
(Washington University, St. Louis, Mo.) and Barbara Sherry (North Carolina
State University, Raleigh, N.C.), respectively. Mice were bred under specific-
pathogen-free conditions in the Department of Laboratory Animal Medicine
breeding colony facilities at the University of North Carolina, Chapel Hill.
Mouse studies were performed in an environmentally controlled room in a
biosafety level 3 facility. CD-1 mice obtained commercially were acclimatized for
7 days. 129Sv/Ev and IFN-a/bR2/2 mice, which were bred in the same building,
were acclimatized for 2 to 5 days in the biosafety level 3 laboratory before
experimental manipulation. Standard mouse chow and water were provided ad
libitum. Mice were between 6 and 8 weeks old when inoculated with virus.
For the morbidity and mortality studies, mice (8 to 11 per experimental group)
were anesthetized in a Metofane-saturated chamber and inoculated s.c. in the
left rear footpad (LRFP) or intracranially (i.c.) with 103 PFU of virus diluted in
endotoxin-free PBS containing 1% donor calf serum (DCS) in a 10-ml volume by
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using a 27-gauge needle and a 100-ml Hamilton syringe. Mock-infected animals
received diluent alone. All mice except for IFN-a/bR2/2 mice were observed
and weighed every 24 h for 14 days. IFN-a/bR2/2 mice were observed every 12 h.
The clinical signs of disease included ruffled fur, paresis, ataxia, and/or paralysis.
Morbidity was defined as greater than 10% weight loss and/or clinical signs for
two or more consecutive days. To confirm a productive infection in the surviving
mice, they were challenged with 104 PFU of V3000 inoculated intraperitoneally
in a 100-ml volume and were scored for morbidity and mortality for 14 days. All
previously inoculated mice survived this lethal challenge without morbidity.
To determine in vivo virus growth kinetics, mice were inoculated s.c. in the
LRFP with 103 PFU of virus. At various times postinoculation, three mice per
experimental group were anesthetized with Metofane, the thoracic cavity was
opened, and blood was collected by cardiac puncture. The serum, separated in
microtainer tubes, was aliquoted and stored at 270°C. Each mouse was then
perfused with PBS–1% DCS to minimize the presence of blood-associated virus
in the organs to be collected. DLN, spleen, thymus, and brain were collected, and
PBS–1% DCS supplemented with Ca1 and Mg1 was added to make 20% (brain)
or 10% (other organs) (wt/vol) suspensions in Kontes microfuge tubes. Samples
were homogenized (Kontes pestles) after one freeze-thaw and clarified by cen-
trifugation at 10,000 3 g. Samples were stored at 270°C prior to processing.
Virus titers were determined by a standard BHK-21 plaque assay.
Cells and in vitro infections. BHK-21 cells, murine L929 fibroblasts (ATCC
CCL-1), and murine Swiss 3T3 fibroblasts (ATCC CCL-92) were maintained in
alpha-minimum essential media (Gibco) supplemented with 10% DCS, 10%
tryptose phosphate broth, 0.29 mg of L-glutamine/ml, 100 U of penicillin/ml, and
0.05 mg of streptomycin/ml (37°C, 5% CO2). Primary bone marrow macrophages
(BMMF) from 129Sv/Ev and IFN-a/bR2/2 mice were generated as previously
described (17). Briefly, the bone marrow cells were collected by flushing the bone
marrow cavity of the femur and tibia bones of cervically dislocated mice with cold
growth media. The cells were pelleted by centrifugation (60 3 g, 4°C, 8 min) and
resuspended in low-endotoxin Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 10% fetal bovine serum (Gibco), 2 mM L-glutamine, 100 U
of penicillin/ml, 0.05 mg of streptomycin/ml, and 20% of L-cell-conditioned
media. The cells were seeded onto low-adherent bacterial dishes and allowed to
differentiate for 7 to 10 days.
For the in vitro growth curves, the BMMF were removed from the low-
adhesion dishes by using enzyme-free cell dissociation buffer (Sigma) and then
were seeded into 24-well plates at a density of 5 3 105 cells/well. The BHK, L929,
and 3T3 cells were seeded into 60-mm-diameter dishes and incubated at 37°C
with 5% CO2. When the monolayers were 80 to 90% confluent, the media were
removed and the cells were infected at a multiplicity of infection (MOI) of 5 to
12 PFU/cell. After 1 h of adsorption at 37°C, the monolayers were washed three
times with PBS–1% DCS at room temperature, and complete growth medium
was added to each dish. At different times p.i., 70- or 20-ml aliquots of media
were collected and an equal volume of fresh media was added to keep the
volume constant. Samples were frozen at 270°C until analysis by plaque assay.
IFN-a/b assay. The levels of murine IFN-a/b present in serum from infected
mouse and in supernatants from infected cell cultures were measured by a
standard biological assay on L929 murine fibroblasts as previously described (58).
Briefly, L929 cultures in 96-well plates were treated with standard murine IFN-
a/b (Lee Biomolecular) (twofold dilutions ranging from 1,000 to 0.49 IU/ml) or
twofold dilutions of the experimental samples, previously acid treated and neu-
tralized. After 24 h of IFN-a/b treatment, the cells were infected with 2 3 105
PFU of encephalomyocarditis virus (EMCV)/well in a 50-ml volume and incu-
bated at 37°C for 24 h. The remaining cells were then stained with 1% crystal
violet. The percent CPE in each well was scored by direct observation. The
IFN-a/b titers (IU/ml) were calculated based on the standard curves generated
with commercial IFN-a/b; the end-point titer was calculated from the dilution of
IFN-a/b required to protect 50% of the cell monolayer from EMCV-induced
CPE.
IFN-a/b sensitivity assay. The relative sensitivity of V3000 and V3043 to
murine IFN-a/b was measured in murine fibroblast L929 cells and Swiss 3T3 cells
in a cell viability assay. The cells were maintained in alpha-minimum essential
media as described above and used within five passages post-thaw. Cells seeded
in 96-well plates were treated with twofold dilutions of standard murine IFN-a/b
(Lee Biomolecular) in triplicate in doses ranging from 505 to 0 IU/ml. After 24 h
at 37°C, the cells were infected with 2 3 106 PFU of virus (V3000 or V3043)/well
or virus diluent in a volume of 50 ml in the presence of 20,000 IU of rabbit
anti-murine IFN-a/b antibodies/ml (55,000 NIH neutralizing units per ml) (Lee
Biomolecular) to minimize the effect of virus-induced IFN-a/b. At 72 hpi, cell
viability was determined by colorimetric quantification using the MTT assay
(mitochondrial dehydrogenase substrate) (Sigma M5655) as described previously
(52). Internal controls on each plate consisted of unprimed infected cells, IFN-
a/b-primed uninfected cells, and unprimed uninfected cells. The percentage of
viable cells in each well was calculated relative to that of the uninfected controls.
These values were used to calculate the percentage of CPE [(1 2 fraction of
viable cells) 3 100].
RNA isolation and analysis by RPA. L929 cells grown in 60-mm-diameter
dishes were treated with 0, 21, or 500 IU of murine IFN-a/b/ml for 24 h at 37°C.
The media were removed and the cells were infected for 1 h at 37°C with V3000
or V3043 at an MOI of 4 PFU per cell. The inoculum was removed and replaced
with prewarmed media. At 4 hpi, cells were placed on ice and harvested for total
cytoplasmic RNA by using the Ultraspec II RNA isolation system (Biotecx). The
levels of viral RNA were detected by an RNase protection assay (RPA) using the
RPAII system (Ambion). A negative-sense VEE-specific riboprobe for the de-
tection of plus-strand genomic and subgenomic VEE RNA was constructed by
inserting the 375-bp BsrGI-BsgI fragment (nt 1925 to nt 2290) of V3000 into the
SmaI-HindIII-digested pGEM-3 plasmid. The pG3V VEE plus-sense specific
probe was made by using the resulting plasmids, which were linearized at the
unique BsrGI site. In vitro T7 polymerase transcription reaction mixtures (Maxis-
cript; Ambion) containing [a-32P]UTP generated a 586-nt radiolabeled probe
that would produce 405- and 163-nt protected fragments corresponding to
genomic and subgenomic RNA, respectively. As an internal control for this
assay, a pGEM-GAPDH plasmid, kindly provided by Charles Rice (School of
Medicine, Washington University, St. Louis, Mo.), was used to generate a spe-
cific probe for the detection of cellular control GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) mRNA. The undigested probe was 130 bp and the
protected fragment was 116 bp. Ten micrograms of total RNA was hybridized
overnight at 45°C in 30 ml of hybridization buffer to a molar excess of each
radiolabeled probe (routinely 1 3 106 to 2 3 106 cpm). Unhybridized RNA was
digested with RNase T1/RNase A mix, and the remaining RNA was precipitated.
The protected radiolabeled RNA was analyzed in 6% acrylamide–8 M urea–
Tris-borate-EDTA gels and visualized with a phosphorimager.
RESULTS
A single change in the 5* UTR of the VEE genome attenuates
the virus in mice after s.c. and i.c inoculations. To assess the
individual contribution of the 59 UTR nt3A mutation to the
attenuation of VEE, we introduced that single change into the
virulent, TRD-derived, full-length cDNA clone (pV3000) and
completely sequenced the mutagenized region to ensure that
no additional changes had been introduced. The virulence of
the resulting clone-derived virus, V3043, was determined by
comparing the morbidity and mortality rates of V3000 and
V3043 in adult 129Sv/Ev mice after s.c. and i.c. inoculation
(Table 1). As has been shown previously for CD-1 mice (4, 13),
TABLE 1. Virulence of V3000 and V3043 in adult 129Sv/Ev mice inoculated with 103 PFU of virus by s.c. and i.c. routes
Virus













V3000 100 (11/11) 100 (11/11) 7.7 6 0.9 100 (8/8) 100 (8/8) 6.1 6 1.2
V3043 0 (0/11) 0 (0/11) NAa 100 (8/8) 0 (0/8) NA
a NA, not applicable.
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V3000 at a dose of 103 PFU was virulent in 129Sv/Ev mice
(100% morbidity and 100% mortality) following s.c. or i.c.
inoculation, with similar average survival times (AST) to those
in CD-1 mice. In contrast, no mortality was observed in mice
inoculated with V3043 by the s.c. route, nor did they show
clinical signs of disease. By the i.c. route, all the mice inocu-
lated with V3043 showed signs of disease (ruffled fur, paresis,
and/or more than 10% weight loss) but nevertheless survived
the infection (100% morbidity, 0% mortality). Similar morbid-
ity and mortality scores were obtained with outbred CD-1 mice
inoculated s.c and i.c. with V3043 (data not shown). All the
mice infected with V3043 were protected against a lethal chal-
lenge with 104 PFU of V3000, confirming that they had under-
gone a productive V3043 infection.
Replication and spread of V3043 mutant virus in the mouse.
To determine the point at which the replication of V3043 was
restricted in the mouse, time course studies were performed
and the kinetics of virus replication in various tissues (DLN,
spleen, serum, and brain) were determined after inoculation
with 103 PFU of either V3000 or V3043 in the LRFP (Fig. 1A
to D). At 12 hpi, replication of both viruses in the DLN and
spleen resulted in similar titers. After 24 hpi, the titers of
V3043 in the spleen and serum started to decline. By 48 hpi,
V3043 titers had dropped 2 to 2.5 logs from the peak titer, and
by 72 hpi, V3043 was below the limit of detection in the serum,
while V3000 titers were still 3 to 4 orders of magnitude higher.
In the DLN, the drop in titer was slower than that in the spleen
and serum, and the difference in titers between V3000 and
V3043 was evident only by 96 hpi (data not shown). In the
brains of mice inoculated s.c., there were detectable levels of
V3000, but not V3043, at 24 hpi. The V3000 titers increased
thereafter until death, while the V3043 titers peaked at 48 hpi,
with only one out of three mice showing titers above the limit
of detection. V3043 titers declined to below the limit of detec-
tion by 96 hpi (data not shown). Therefore, V3043 was able to
replicate in the same tissues as V3000 and reached comparable
titers early in the infection. However, V3043 titers were lower
at 48 hpi in spleen, serum, and brain. V3043 viremia was lower
and of shorter duration than that of V3000. Serum titers of
both viruses were above the threshold required for neuroinva-
sion in the mouse (K. A. Bernard et al., personal communica-
tion). When V3043 was injected directly into the brain, the
kinetics of replication in brain were similar to those of V3000
at early times p.i.; however, the mutant virus was cleared from
the brain while the wild-type virus continued to replicate until
the death of the animal (data not shown).
V3043 is as virulent as V3000 and grows to similar titers in
IFN-a/bR2/2 mice. The rapid, early clearance of V3043 from
FIG. 1. Virus titers of V3000 and V3043 in 129Sv/Ev mouse tissues. Six- to 8-week-old 129Sv/Ev mice were inoculated s.c. in the LRFP with
103 PFU of V3000 (solid bars) or V3043 (hatched bars). At the indicated times p.i., three mice per group were sacrificed and the following tissues
were harvested: DLN (A), spleen (B), serum (C), and brain (D). Virus titers were determined by plaque assay of BHK-21 cells. The values are
the geometric mean titers (log10 PFU/milliliter or gram) of three mice. Error bars represent standard deviations. The lower limit of detection is
indicated by a broken line. p, all samples had virus titers below the limit of detection; pp, one out of three samples had virus liters above the limit
of detection.
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spleen and serum suggested two possible mechanisms of nt3A
attenuation. The nt3A mutation may have a slightly reduced
rate of replication in one or more cell types that is detectable
only after amplification through several rounds of replication.
Alternatively, the mutation may affect the interaction of the
virus with some aspect of the host nonspecific innate immune
response, such as induction of or sensitivity to IFN-a/b. To
distinguish between these two possibilities, V3000 and V3043
infections were compared in IFN-a/bR2/2 mice (35), the con-
genic background strain 129Sv/Ev, and cells derived from
them. We hypothesized that in the absence of a functional
IFN-a/b pathway, any effect of the nt3A mutation on the
intrinsic growth of the virus independent of the IFN-a/b re-
sponse would be detected. The virulence of V3000 and V3043
in the IFN-a/bR2/2 mouse was compared to that in the con-
trol mice after inoculating the animals s.c. with 103 PFU of
either virus (Fig. 2). V3000 infection of either the IFN-a/
bR2/2 or normal 129Sv/Ev mouse resulted in 100% mortality,
but the AST was significantly shorter in the IFN-a/bR2/2
mouse (30 h) than in the control 129Sv/Ev mouse (7.7 days).
The results indicate that V3000 replication in control mice is
significantly restricted by IFN-a/b but is not sufficiently re-
stricted to prevent the virus from causing a fatal encephalitis,
as reported earlier (15). In contrast to results obtained with the
129Sv/Ev control mouse, in the IFN-a/bR2/2 mouse V3043
was as virulent as the wild-type virus, causing 100% mortality
with an AST similar to that of V3000 (30 h). Even when mice
were inoculated with lower doses (102, 10, and 1 PFU), V3043-
infected IFN-a/bR2/2 mice showed the same AST of V3000-
infected mice (30 h).
To compare the replication and spread of V3000 and V3043
virus in the IFN-a/bR2/2 mouse, 6- to 8-week-old mice were
inoculated in the LRFP with 103 PFU of either virus. At dif-
ferent times p.i., serum and selected organs were harvested in
triplicate as described for Fig. 1. The levels of virus in the
DLN, spleen, and serum of the IFN-a/bR2/2 mice were equiv-
alent for both V3000 and V3043 and increased continuously
with no evidence of clearance until the death of the animal
(Fig. 3). Under these conditions, V3043 did not show a growth
restriction in the organs tested, except for the brain at 27 hpi,
in which the titers of V3043 were consistently lower than those
of V3000.
The experiments depicted in Fig. 1 and 3 were performed in
parallel, allowing comparison of the virus titers in the IFN-a/
bR2/2 mouse (Fig. 3) with those in the 129Sv/Ev mouse (Fig.
1). At 12 hpi, the titers of both viruses in the DLN of the
IFN-a/bR2/2 mice were equivalent to those in the 129 Sv/Ev
mice, suggesting that early replication in the DLN was not
significantly affected by either the nt3A mutation or the IFN-
induced antiviral state. However, in the next 24 h, IFN-a/b
played a crucial role and determined the kinetics of replication
and spread for both viruses and the outcome of the infection by
V3043.
Growth of V3043 in cell culture is reduced in the pres-
ence, but not in the absence, of a functional IFN-a/b path-
way compared to that of V3000. To further examine the
mechanism of attenuation of this mutation, the in vitro
growth phenotypes of V3000 and V3043 were examined.
Growth curves were performed in mouse fibroblast cell lines
L929 and Swiss 3T3, in the BHK-21 cell line, and in primary
BMMF derived from 129Sv/Ev or IFN-a/bR2/2 mice (Fig.
4). Triplicate monolayers of cells were infected with either
virus at an MOI of 5 to 12 PFU/cell (PFU determined on
BHK cells). At these MOIs, virtually 100% of the BHK,
L929, and 3T3 cells and IFN-a/bR2/2 BMMF were in-
fected, as determined by infecting cells at equivalent MOIs
with replicon particles 5005-3000 (nt3G) or 5505-3000
(nt3A) and measuring the percentage of cells expressing
GFP. We consider these conditions representative of single-
step growth curves. At the same MOI, less than 3% of 129
BMMF expressed GFP, reflecting a reduced permissivity to
VEE replication, determined mainly by the status of the
IFN-a/b system (see below). The specific infectivity (particle
per PFU ratio) of V3000 and V3043 in BHK-21 cells is
equivalent (K. A. Bernard and R. E. Johnston, unpublished
observation); therefore, infections at the same MOI (BHK
PFU/cell) can be compared. The relative infectivity of both
viruses in the other cell lines was similar when compared by
infecting the cells with GFP-expressing replicon particles
derived from the wild-type or the mutant sequence and
measuring the percentage of cells expressing GFP.
Even though there were variations in permissivity and
growth kinetics of V3000 infection among the cell types tested,
V3043 virus grew slower and to lower titers than V3000 in
BHK-21, L929, and Swiss 3T3 cells and BMMF derived from
129Sv/Ev mice (Fig. 4A to D). Similar results were seen in
Neuro2A cells and primary mouse embryo fibroblasts from
CD-1 mice (data not shown). Although the virus titers in the
BMMF derived from 129Sv/Ev were low, V3043 replication
was even more restricted than that of V3000 (Fig. 4D), as
shown for the other more permissive cell lines.
These experiments were designed to infect all permissive
cells at time zero to limit the factors affecting the growth of
V3043 to either an intrinsic growth defect or an autocrine or
endogenous IFN-a/b response. We hypothesized that in cells
derived from IFN-a/bR2/2 mice, in which virus growth cannot
be affected by an autocrine or paracrine IFN-a/b response, an
attenuated growth phenotype would be the result of an intrin-
sic growth defect. In BMMF cells derived from the IFN-a/
bR2/2 mice, both viruses grew to titers several orders of mag-
FIG. 2. Survival of 129Sv/Ev (closed symbols) and IFN-a/bR2/2
(open symbols) mice infected with V3000 or V3043. Six- to 8-week-old
mice, 11 mice per group, were inoculated in the LRFP with 103 PFU
of V3000 or V3043. The mice were observed every 6 h for the first 48 h
and every 24 h for 12 days. The survival curves of V3000 and V3043 in
the IFN-a/bR2/2 mice are superimposable.
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nitude higher than those in cells from normal controls.
Interestingly, in contrast to all other cell types, V3043 grew to
titers similar to or even higher than those of V3000 in BMMF
from IFN-a/bR2/2 mice, suggesting that the nt3A mutation
does not cause a major intrinsic growth defect and that when
the IFN-induced antiviral response was functional, it was more
efficient in controlling V3043 infection than V3000 infection.
The growth characteristics of V3000 and V3043 in the BMMF
from IFN-a/bR2/2 mice were consistent with the in vivo re-
sults presented in the previous section. These results supported
the hypothesis that IFN-a/b plays an important role in the
attenuated phenotype of V3043 and suggested that any IFN-
a/b-independent effect of nt3A mutation on virus growth
would play only a minor role.
Induction of IFN-a/b by V3000 and V3043 infections in cell
culture and in vivo. To further dissect the role of IFN-a/b in
the attenuation of V3043, the nt3A mutation was examined for
its effect on the ability of VEE to induce IFN-a/b. The pro-
duction of murine IFN-a/b in vivo and in vitro was measured
following infection with V3000 and V3043. The amount of
IFN-a/b present in the sera of CD-1 mice inoculated s.c. with
103 PFU of V3000 or V3043 was proportional to the serum
virus titers and followed similar kinetics. Peak titers of IFN-a/b
were observed 18 to 24 hpi in both V3000- and V3043-infected
mice, but higher titers were induced by the virulent V3000 (up
to 80,000 IU/ml) than by V3043 (up to 20,000 IU/ml) (data not
shown). Because serum IFN-a/b levels may reflect the levels of
virus replication and spread in the peripheral tissues, we com-
pared the wild-type and the mutant viruses in their ability to
induce IFN-a/b after a single replication cycle. Wild-type
R5005-3000 and mutant R5505-3000 VRPs, which can only
undergo one round of replication, were used to infect 129Sv/Ev
and IFN-a/bR2/2 mice (Fig. 5A). Replicon particles contain a
VEE replicon genome containing the GFP gene instead of the
structural protein genes, with either nt3G (R5005) or nt3A
(R5505). At 6 hpi, both replicons induced detectable levels of
serum IFN-a/b in both strains of mice. No differences in in-
duction were found between the wild-type and mutant VRP
infections, nor between the two strains of mice at this time. At
12 hpi, the IFN-a/b levels in the serum of IFN-a/bR2/2 mice
had dropped significantly compared to the titers in the 129
Sv/Ev mice, but titers of the different VRPs were similar within
each mouse strain. At 24 hpi, the levels of IFN-a/b in the
serum had dropped in both mouse strains, being lower for the
IFN-a/bR2/2 mice (at or below the lower limit of detection of
the assay) and again showing no differences between them for
the different VRPs. By 48 hpi, IFN-a/b could not be detected
in any sample (data not shown). Therefore, the IFN-a/b in-
duction after a single round of replication in vivo was not
different in mice infected with the wild type compared to those
infected with nt3A mutant VRP. Interestingly, the kinetics of
IFN-a/b induction were different depending on whether or not
the mice expressed the receptor for IFN-a/b. The IFN-a/b
induced early was not dependent on the presence of the IFN-
a/b receptor, while later, in the absence of the IFN receptor,
less IFN was induced.
FIG. 3. Virus titers of V3000 and V3043 in IFN-a/bR2/2 mouse tissues. Six- to 8-week-old IFN-a/bR2/2 mice were inoculated s.c. in the LRFP
with 103 PFU of V3000 (solid bars) or V3043 (hatched bars). At the indicated times p.i., three mice per group were sacrificed, tissues were
harvested, and virus titers were determined as indicated in Fig. 1. The following tissues were harvested: DLN (A), spleen (B), serum (C), and brain
(D). The values are the geometric mean titers (log10 PFU/milliliter or gram) of three mice. Error bars represent the standard deviations. The lower
limit of detection is indicated as a broken line. p, samples with virus titers below the limit of detection.
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To compare IFN-a/b induction in vitro, BMMF cells from
IFN-a/bR2/2 mice were infected with either replicon particle
preparation at an MOI of 20. At 18 and 24 hpi, the titers of
IFN-a/b in the culture supernatants were determined by bio-
assay on L929 cells (Fig. 5B). The IFN-a/b induced in the
absence of the IFN-a/b receptor and in further rounds of
replication was equivalent at 18 and 24 hpi in the culture
supernatants whether cells were infected with V5005-3000 or
V5505-3000, confirming the in vivo results.
V3043 is more sensitive than V3000 to exogenous IFN-a/b in
infected cell cultures. We next examined the effect of the nt3A
mutation on the sensitivity of the virus to the antiviral effect
induced by IFN-a/b. Two different assays were used to mea-
sure IFN-a/b sensitivity. First, mouse fibroblast L929 or Swiss
3T3 cells that had been pretreated with increasing concentra-
tions (0 to 506 IU/ml) of murine IFN-a/b for 24 h were in-
fected with V3000 or V3043 at an MOI of 10 to 20. The
readout was virus-induced CPE at 72 hpi. To minimize the
effect of the IFN-a/b produced by the infected cells on the
readout of the assay, cells were infected in the presence of
20,000 IU of anti-IFN-a/b antibodies/ml, since in their ab-
sence, V3043 was not able to cause full CPE in the mock-IFN-
treated controls. The dose of anti-IFN-a/b antibodies was es-
timated based on the maximum levels of IFN-a/b produced in
such infected cultures (up to 10,000 IU/ml; data not shown).
For both viruses, pretreatment with IFN-a/b decreased the
percentage of cells exhibiting CPE compared to that of the
untreated control, indicating that both were sensitive to the
antiviral effects of IFN-a/b (Fig. 6). The sensitivity curve of
V3000 in L929 cells was similar to that of the EMCV indicator
virus used in this assay (data not shown), with concentrations
of 32 to 63 IU of IFN/ml protecting 50% of the monolayer
from virus-induced CPE. The sensitivity curve of V3043 was
shifted to the left, reflecting a sensitivity to IFN-a/b that was 8-
to 10-fold higher than that of V3000 (Fig. 6A). IFN-a/b at 8
IU/ml was able to protect 50% of the monolayer from V3043-
induced CPE under infection conditions in which both viruses
were able to cause close to 100% CPE in the untreated control.
The increased sensitivity of V3043 to IFN-a/b was more dra-
matic in Swiss 3T3 cells, in which 0.5 IU of IFN-a/b/ml pro-
tected 50% in the V3043-infected culture, while more than 506
IU of IFN-a/b/ml was required to protect 50% in the V3000-
infected culture (Fig. 6B).
The increased sensitivity of V3043 to IFN-a/b was also
shown by analysis of viral RNA synthesis using an RPA. L929
cells were pretreated for 24 h with IFN-a/b at a high dose (500
IU/ml) or a low dose (21 IU/ml) or were mock treated with
diluent. The cells were then infected with V3000 or V3043 at
an MOI of 4. At 4 hpi, total cytoplasmic RNA was extracted for
analysis of VEE genomic and subgenomic RNA by RPA. The
levels of genomic VEE RNA in the untreated control cells
were two- to threefold higher in the V3043-infected cells than
FIG. 4. In vitro growth of V3000 and V3043 in L929 cells (A), Swiss 3T3 cells (B), BHK-21 cells (C), and primary BMMF (D) from 129Sv/Ev
(closed symbols) and IFN-a/bR2/2 (open symbols) mice. Monolayers grown in 60-mm-diameter dishes were infected in triplicate with V3000 (solid
line) or V3043 (broken line) at an MOI of 5 to 12. After 1 h of adsorption at 37°C, the monolayers were washed three times and complete media
were added. The first aliquot was collected at this time. Aliquots of culture media were collected at various times p.i., and equal volumes of fresh
media were replaced every time. Virus titers were determined by a plaque assay on BHK-21 cells.
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in the V3000-infected cells (Fig. 7). This result is consistent
with the one-step growth curves of the IFN-a/bR2/2 cells and
with the hypothesis that the attenuation of V3043 is not the
result of a decreased ability of V3043 to replicate. When cells
were pretreated with 500 IU of murine IFN-a/b/ml, viral RNA
was not detected in either V3000- or V3043-infected cells,
indicating that at high doses of IFN-a/b, the replication of both
viruses was suppressed, consistent with the results in Fig. 6A.
In contrast, when cells were treated with 21 IU of IFN-a/b/ml,
the levels of V3043 RNA were reduced 78% in comparison to
those of the untreated control, while the levels of V3000 RNA
were reduced by only 9%, even though the RNA levels in the
untreated control were higher for V3043. This result suggests
that relative to the wild type, the mutation at nt 3 in the V3043
59 UTR mediates a higher level of RNA replication, higher
intracellular dsRNA levels, and greater sensitivity to IFN-a/b-
induced antiviral effector pathways and, consequently, attenu-
ation in vivo.
DISCUSSION
The study of alphavirus virulence from a genetic perspec-
tive has yielded a number of interesting observations, per-
haps none more interesting than the dramatic effects that a
single nucleotide change can have on the course of disease
in an animal. This is illustrated by the many examples of
single-codon changes in alphavirus genomes, and indeed
alternative amino acid substitutions at a given codon, that
profoundly alter virulence and organ tropism (2, 4, 9, 13, 18,
25, 40, 51). The 59 UTR of the genome of alphaviruses,
which has been implicated in neurovirulence (10, 23, 26, 27,
33), is a case in point. In mice, a single nucleotide change in
the 59 UTR of VEE or Sindbis virus acts synergistically with
determinants in the E2 glycoprotein to cause attenuation
(10, 23, 33). In this study, we have examined the individual
contribution of a single nucleotide change in the VEE 59
UTR and have shown that it changes a virus which invariably
causes 100% mortality to one which causes no deaths by
either a peripheral or i.c. route of inoculation. In dissecting
the in vivo and in vitro growth properties of the mutant
virus, we have unveiled a major role for IFN-a/b in the
attenuation of this single mutant virus. Our study contrib-
utes not only to a better understanding of alphavirus viru-
lence but also of how the interplay between the virus genet-
ics and the innate immune response affects the outcome of
the infection.
Comparison of the pathogenesis of V3000 and V3043 re-
vealed that the two viruses grew in the same tissues and rep-
licated to similar titers through the first 12 hpi. After this time,
however, a restriction in mutant replication was detected, peak
titers in tissue and serum were reduced, clearance from the
periphery was accelerated, and invasion of the central nervous
system was delayed and less frequent. This profile suggested
that the mutation in the 59 UTR did not necessarily impede
growth at the single-cell level but more likely caused V3043 to
be more susceptible to an early host response.
The relative roles of the innate response to alphavirus in-
fection, such as through the IFN-a/b system, and classical
adaptive immune responses have been examined (5, 5a, 15, 16,
25, 28, 30, 35, 48, 57). In genetically modified animals lacking
elements of the adaptive immune system, alphavirus infections
appear less damaging than those in their immunologically in-
tact counterparts. However, the virus typically is not cleared
from the animal, which may ultimately die from continued
virus replication (5a, 11, 29, 30). In contrast, defects in the
IFN-a/b system render mice extremely susceptible to lethal
infection (15, 19, 35), even with alphaviruses that do not cause
any clinical illness at all in normal adult animals (48). Clearly,
the IFN-a/b system provides an earlier and more protective
benefit than adaptive immunity, the latter being demonstrably
harmful in some cases.
In the work presented here, a significantly shorter AST and
a 10,000-fold increase in virus titers in the IFN-a/bR2/2 mice
FIG. 5. In vivo (A) and in vitro (B) induction of IFN-a/b in
129Sv/Ev and IFN-a/bR2/2 mice or cells derived from them. (A) Six-
to 8-week-old 129Sv/Ev and IFN-a/bR2/2 mice were inoculated s.c. in
the LRFP with 105 IU of wild-type R5005-3000 or mutant R5505-3000
replicons expressing GFP. At 6, 12, and 24 hpi, three mice per exper-
imental group were euthanatized for blood collection. Aliquots of
serum were frozen at 270°C and were thawed only once for IFN-a/b
detection by using a bioassay on L929 cells and EMCV as indicator
virus. Values are the averages of data from three mice, and the error
bars represent the standard deviations. The lower limit of detection is
indicated as a broken line. p, samples with virus titers below the limit
of detection (dotted line). The levels of IFN-a/b in the mock-infected
mice were below the limit of detection. (B) Monolayers of BMMF
from IFN-a/bR2/2 mice prepared as described for Fig. 4 were infected
with R5005-3000 or R5505-3000 GFP-expressing replicons at an MOI
of 20. At 18 and 24 hpi, the media were collected and clarified by
centrifugation and aliquots were frozen until used in IFN-a/b assays as
described for panel A.
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compared to those in normal mice were evidence that IFN-a/b
does significantly inhibit VEE replication. These results were
consistent with the mortality and AST of V3000 in IFN-a/
bR2/2 mice compared to those in the control mice reported by
Grieder et al. (15). The comparable virulence of V3043 and
V3000 in the IFN-a/bR2/2 mice was consistent with the V3043
virus being more susceptible than V3000 to the early host
response. Any mutation that reduces the replication compe-
tence of a virus could render it more susceptible to an early
immune response. However, we predicted that an important
growth defect would impair growth even in the absence of a
functional IFN response, as has been shown for the Sindbis
attenuating mutant TRSB-R114 (48). With the exception of
brain titers, this was not the case for V3043. V3043 brain titers
were consistently lower than V3000 titers at 24 hpi, suggesting
that tissue-specific differences in growth between V3000 and
V3043 also could contribute to the attenuated phenotype.
Therefore, our in vivo data do not completely rule out a minor
effect of the nt3A mutation on virus replication at the single-
cell level, which could also indirectly result in a virus more
susceptible to an early host response. A closer examination of
the effect of nt3A on different steps in the replication cycle of
the virus in cells lacking a functional IFN-a/b pathway is nec-
essary to better understand any IFN-independent effect. There
may be an altered interaction between the 59 UTR and specific
cell factors involved in translation or replication, higher en-
dogenous levels of antiviral enzymes in different tissues, or an
undefined IFN-independent mechanism in these tissues.
The attenuated phenotype of V3043 observed in vivo in
the normal mouse was mimicked in cultured mouse and
hamster cell lines and 129Sv/Ev mouse primary cells, in
which V3043 replicated more slowly and to lower titers than
V3000. The only cell culture in which V3043 did not show
reduced growth was in the BMMF from IFN-a/bR2/2 mice,
consistent with the results from the in vivo infections that
suggested a significant role for IFN-a/b in the reduced
growth of V3043 in normal cells. We predicted that in one-
step growth curves produced in the absence of a functional
IFN-a/b system, any IFN-independent intrinsic growth de-
fect in V3043, such as reduced viral RNA or protein syn-
thesis, would be revealed. No growth reduction was ob-
served; V3043 grew as well as, or better than, V3000 in cells
from the IFN-a/bR2/2 mice, suggesting that the mutant
virus did not have an intrinsic growth restriction in these
cells. Interestingly, the higher V3043 titers in the absence of
a functional IFN system support the hypothesis that nt3A
causes an early increase in genomic RNA replication (Fig.
7). This could increase the induction or the activation of
IFN-induced antiviral proteins, which in the presence of a
functional IFN-a/b response could result in increased sen-
sitivity to IFN-a/b but in its absence could result in higher
virus titers. The low permissivity of normal BMMF for VEE
replication could be the result of an autocrine or paracrine
IFN-a/b response mediated by IFN-a/b released by the in-
fected cells that would induce an antiviral state in the in-
fected and neighbor cells through the IFN-a/b receptor
(48). Alternatively, a priming effect mediated by high en-
dogenous levels of antiviral enzymes at the time of the
infection could result in low permissivity.
Grieder and Nguyen (14) studied the growth kinetics of
V3000 in mouse primary peritoneal macrophages, either qui-
escent or activated with lipopolysaccharide or IFN-g prior to
infection. Their results showed peak titers of about 104
PFU/ml at 18 hpi when infected at an MOI of 1. These titers
are comparable to the ones reported here for the BMMF, even
though our experiments were performed at higher MOIs (5 to
12) and used macrophages with a different phenotype and
stage of differentiation.
To explain the in vivo and in vitro phenotypic differences
observed in the presence and absence of a functional IFN
pathway, we proposed two hypotheses: (ii) V3043 could be
inducing higher levels of IFN-a/b than V3000 and/or (ii)
V3043 could be more sensitive to the antiviral response in-
duced by IFN-a/b.
To address IFN-a/b induction, we used identical virus
particles carrying either V3043 or V3000 replicon genomes
so that IFN-a/b induction could be measured without the
confounding effects of multiple rounds of viral replication
and subsequent alterations in the physiology of the host. We
saw no differences in IFN-a/b induction between mutant
FIG. 6. IFN-a/b sensitivity assay of L929 (A) and 3T3 (B) cells. Monolayers of L929 cells in 96-well plates were treated with twofold dilutions
of murine IFN-a/b (concentrations ranging from 506 to 0 IU/ml) for 24 h. Mice were infected with either V3000 or V3043 at an MOI of 10 to 20
PFU/cell in the presence of 20,000 IU of anti-IFN-a/b antibodies/ml to minimize any possible autocrine effects of IFN-a/b induction. The
percentage of CPE was measured at 72 hpi by the MTT colorimetric assay.
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and wild-type replicon particles in either normal or IFN-a/
bR2/2 mice. We would predict that higher levels of RNA
synthesis by V3043 would induce higher levels of IFN-a/b,
but our assays did not detect any difference. However, an
interesting observation was made while addressing this
question. Analysis of the kinetics of IFN-a/b induction after
a single round of replication showed a prompt and transient
response. However, early IFN-a/b levels (6 hpi) were not
affected by the absence of the IFN-a/b receptor, while the
faster drop of IFN-a/b titers in the sera of IFN-a/bR2/2
mice compared to those of the normal mice suggested that
feedback signaling through the IFN-a/b receptor was re-
quired for the continued production of IFN-a/b at 12 and 24
hpi. Recent studies have shown that in the absence of Stat1,
only IFN-a4 is induced in response to Newcastle disease
virus infection, while the induction of other species of IFN-a
require signaling through the JAK-STAT pathway (involv-
ing new protein synthesis of IFN itself and IRF7) (32). This
observation could explain our results of differential induc-
tion of IFN-a/b by both V3000 and V3043 in the IFN-a/
bR2/2 mice compared to induction in the normal mice.
When we compared the antiviral effects of murine IFN-a/b
on V3000 and V3043 infections of murine fibroblasts, V3043
was 8- or .100-fold more sensitive to IFN-a/b in L929 or Swiss
3T3 cells, respectively. The mechanism of IFN-induced pro-
tection in the mouse fibroblasts involves binding of IFN-a and
FIG. 7. Mutant virus is more sensitive to IFN-a/b in L929 cells early in infection at the RNA synthesis level. L929 cells pretreated for 24 h with
0, 21, or 500 IU/ml of murine IFN-a/b were infected with V3000 or V3043 at an MOI of 4 or were mock infected. Total cytoplasmic RNAs were
isolated at 4 hpi, and the levels of VEE plus-strand genomic and subgenomic RNA and of the mRNA for the housekeeping gene GAPDH were
determined by RPA. Lane 1, undigested probes; lanes 2 to 4, 10, 100, and 1,000 ng, respectively, of plus-strand VEE RNA transcripts used as
controls and subjected to the RPA. The presence (1) or absence (2) of IFN-a/b pretreatment is indicated. The concentrations of IFN-a/b (1)
(in IU/milliliter) used are indicated.
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IFN-b to the common receptor on the cell surface, which
triggers a cascade of events through the JAK-STAT pathway.
This results in the transcriptional induction of a large group of
IFN-stimulated genes, including RNA-dependent protein ki-
nase, 29-59 oligoadenylate synthetase, RNase L, MX1, and
adenosine deaminase. In the infected cell, viral dsRNA repli-
cation intermediates bind to the induced RNA-dependent pro-
tein kinase, 29-59 oligoadenylate synthetase, and/or adenosine
deaminase as cofactors in the activation of these activities (62).
Future studies will address the mechanism of increased sensi-
tivity to IFN-a/b by determining what IFN effector mecha-
nisms are active in the inhibition of VEE and what the relative
sensitivity of the wild type and the nt3A mutant virus is to those
antiviral pathways.
Attenuation determinants affecting sensitivity to IFN have
been described for other viral systems. IFN-sensitive mutants
of mengovirus (53) as well as a mutant of Sindbis virus resistant
to mycophenolic acid and ribavirin with increased sensitivity to
chicken IFN (47) have been described. However, the genetic
loci in the virus responsible for the IFN-sensitive phenotype
have not been defined, and the mechanisms that mediate their
increased sensitivity to IFN are poorly understood.
Our results are consistent with previous reports showing
an increased sensitivity to IFN-a/b of VEE strain TC-83 and
horse-avirulent enzootic strains compared to those of their
virulent counterparts (42, 54). These studies with chimeric
viruses showed that IFN-a/b sensitivity segregates with the 59
UTR and nonstructural genes (42). Our studies go further and
associate the IFN-a/b sensitivity phenotype with a single locus
in the 59 UTR.
Alphaviruses are transmitted between vertebrate hosts by
mosquito vectors which acquire the virus by taking a blood
meal from an infected animal at a time of peak viremia (21).
To insure a sufficiently high titer of virus for mosquito trans-
mission, one would anticipate a selective pressure in favor of
high-level virus replication and RNA synthesis. Decreased
RNA synthesis would lead to a reduced viremia and concom-
itantly reduced fitness in nature. On the other hand, high levels
of dsRNA could lead to increased induction of IFN-a/b as well
as increased synthesis and/or activation of IFN-a/b-related an-
tiviral effector mechanisms. Therefore, increased levels of
RNA synthesis could also lead to the same negative fitness
result by evoking elements of the IFN-a/b system. In terms of
pathogenesis, either an increase or decrease in RNA synthesis
would predict decreased virulence. In the case of V3043, early
RNA synthesis is increased, the sensitivity of this virus to
IFN-a/b is increased by 8- to .100-fold, replication in the
animal is decreased, and the virus is avirulent.
Our working hypothesis to link the single nucleotide
change at nt 3 of the 59 UTR to the loss of virulence in mice
is as follows. Although computer-generated RNA secondary
structures only imperfectly predict authentic interactions,
the Zucker programs do suggest that nt 3 is involved in a
stable stem structure (59). Secondary structures of the 59
UTR have been predicted for other alphaviruses (10, 38,
55). The change from G to A in V3043 is predicted to
weaken this structure, which may create a more accessible 59
terminus. This altered structure could affect RNA synthesis
directly, as the 39 end of the negative-strand complement
serves as the promoter for the synthesis of progeny positive-
strand genomes. Alternatively, the 59 and 39 ends of the
genome may interact during RNA synthesis so that alter-
ations in the genomic 59 UTR could affect positive- and/or
negative-strand synthesis. Finally, release of the extreme 59
end of the genome from the stem could increase translation
initiation for the nonstructural protein open reading frame,
leading to increased levels of viral replicase components and
hence increased RNA synthesis. (Preliminary evidence sug-
gests that translation of nonstructural proteins is elevated in
rabbit reticulocyte lysates primed with V3043 RNA and that
higher levels of nonstructural proteins are synthesized in
infected cells in culture.) We would predict that the in-
creased IFN-a/b sensitivity of V3043 is a result of higher
levels of RNA synthesis, leading to increased direct induc-
tion of IFN-a/b-related antiviral effectors, increased activa-
tion of such effectors, or both. Alternatively, increased IFN-
a/b sensitivity could result from slower viral inhibition of
host protein synthesis, allowing continued production of key
antiviral activities in infected cells. This hypothesis is con-
sistent with (i) the highly virulent infection of V3043 in
IFN-a/bR2/2 mice, (ii) the absence of a growth differential
between the wild type and V3043 in cells lacking a func-
tional IFN-a/b system, (iii) the lack of an early growth
inhibition of V3043, followed by decreased titers in organ
and more rapid clearance in normal animals, and (iv) re-
duced virulence.
While a number of individual elements of the hypothesis
remain to be addressed, our characterization of this single
nucleotide change in the 59 UTR presents the opportunity to
pursue a more comprehensive examination of the dynamic
interaction of virus and host at the earliest times in the disease
process.
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